Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?

被引：13
|
作者：
Ferrara, Felicetto [1 ]
机构：
[1] Cardarelli Hosp, Div Hematol, Naples, Italy
来源：
BLOOD CANCER JOURNAL | 2020年 / 10卷 / 01期
关键词：
UPDATE;
D O I：
10.1038/s41408-020-0281-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Comparison of DNA hypomethylating agents and low dose cytarabine in elderly acute myeloid leukemia patients: A meta-analysis.
    Vincelette, Nicole
    Yun, Seongseok
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Venetoclax and Posaconazole Plus Standard Dose Cytarabine or Azacytidine for Newly Diagnosed Acute Myeloid Leukemia
    Tran-Der Tan
    Chiou, Lun-Wei
    BLOOD, 2020, 136
  • [33] Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Luo, Tingyue
    Yu, Sijian
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Deng, Lan
    Liang, Xinquan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Shao, Ruoyang
    Du, Xin
    Jin, Hua
    Liu, Qifa
    JOURNAL OF INTERNAL MEDICINE, 2023, 293 (03) : 329 - 339
  • [34] Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
    de Camargo Magalhaes, Eduardo Sabino
    Hubner, Stefan Edward
    Brown, Brandon Douglas
    Qiu, Yihua
    Kornblau, Steven Mitchell
    LEUKEMIA, 2024, 38 (05) : 1046 - 1056
  • [35] Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
    Eduardo Sabino de Camargo Magalhães
    Stefan Edward Hubner
    Brandon Douglas Brown
    Yihua Qiu
    Steven Mitchell Kornblau
    Leukemia, 2024, 38 : 1046 - 1056
  • [36] Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Liang, Xinquan
    Deng, Lan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Jin, Hua
    Du, Xin
    Liu, Qifa
    BLOOD, 2022, 140 : 2025 - 2026
  • [37] Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers
    Schmalbrock, Laura K.
    Braitsch, Krischan
    Jung, Paul
    Bumeder, Irmgard
    Kiewe, Philipp
    Westermann, Joerg
    Bullinger, Lars
    Keller, Ulrich
    Bassermann, Florian
    Kroenke, Jan
    Rieger, Kathrin
    Goetze, Katharina S.
    BLOOD, 2021, 138
  • [38] Venetoclax Combined with Azacitidine or low-dose Cytarabine for Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplant
    Smith, Katy
    Fathoala, Dina
    Anthias, Chloe
    Easdale, Sandra
    Ethell, Mark
    Potter, Mike
    Mir, Farheen
    Taussig, David
    Nicholson, Emma
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 188 - 189
  • [39] Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
    Li, Yan-Yan
    Ge, Shuai-Shuai
    Huang, Yuan-Hong
    Xu, Ming-Zhu
    Wan, Chao-Ling
    Tan, Kai-Wen
    Tao, Tao
    Zhou, Hai-Xia
    Xue, Sheng-Li
    Dai, Hai-Ping
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [40] Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
    Amador-Medina, Lauro Fabian
    Crespo-Solis, Erick
    Turrubiates-Herna, Francisco Javier
    Santibanez-Bedolla, Karla Edith
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 : S322 - S331
12345